PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer - sprookjes - yvandenbroek - TriplyDB

PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

http://www.wikidata.org/entity/Q34041708

about

Quality of Life in Patients with NSCLC Receiving Maintenance Therapy.Pulmonary Adenocarcinoma Metastatic to the Choroid Diagnosed by Biopsy of an Extrascleral Nodule.MicroRNA-137-regulated AKT serine/threonine kinase 2 inhibits tumor growth and sensitizes cisplatin in patients with non-small cell lung cancer.

P2860

Q38512986-FA100066-B18D-46D8-97CA-8F45070F1D53 Q40709180-0AB93D76-3392-4892-AD24-98C46D46C66A Q55669441-0A89E4B7-4E0E-4AE3-AA4D-50E402754D93

P2860

PARAMOUNT: Descriptive subgroup analyses of final overall survival for the phase III study of maintenance pemetrexed versus placebo following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

http://www.wikidata.org/entity/Q34041708

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

PARAMOUNT: Descriptive subgrou ...... ous non-small-cell lung cancer

@ast

PARAMOUNT: Descriptive subgrou ...... ous non-small-cell lung cancer

@en

PARAMOUNT: Descriptive subgrou ...... ous non-small-cell lung cancer

@nl

type

label

PARAMOUNT: Descriptive subgrou ...... ous non-small-cell lung cancer

@ast

PARAMOUNT: Descriptive subgrou ...... ous non-small-cell lung cancer

@en

PARAMOUNT: Descriptive subgrou ...... ous non-small-cell lung cancer

@nl

prefLabel

PARAMOUNT: Descriptive subgrou ...... ous non-small-cell lung cancer

@ast

PARAMOUNT: Descriptive subgrou ...... ous non-small-cell lung cancer

@en

PARAMOUNT: Descriptive subgrou ...... ous non-small-cell lung cancer

@nl

P1433

Q34041708-1E26B677-6E3C-4909-96C8-F3E33C3401F0

P1476

Q34041708-2AD6EFB6-6E60-4E78-B817-0230C89F84C4

P2093

Q34041708-05DD338F-C607-4178-8582-9EE945154BB0

Q34041708-4EDF73ED-E723-4FD8-A3A8-F59DFDA26754

Q34041708-6CA21456-86A2-4CBF-9BCB-9153D5AEC5D9

Q34041708-B38331F8-7BB2-4979-A000-DE5146C3A6BE

Q34041708-B751462F-CE02-40BD-95A0-C5B8BBF96353

Q34041708-C8778CB9-D4E0-4DDA-B8A9-91F78E4FF957

Q34041708-D9273DCE-8E96-4AED-9990-8EA842ED68D3

Q34041708-EBD0FE23-FC83-4D4E-8CB3-E9F0990A1EB4

Q34041708-EBF6137A-B24D-4ED1-ADA9-C97653331472

P2860

Q34041708-197192E5-9095-4574-85D4-1C31B616FD6C

Q34041708-210DD758-DA06-4C62-9866-B9982C9A225D

Q34041708-38C1975D-3BBA-4B1D-B93D-59AE6A584C7C

Q34041708-4E9E4678-A1AD-4E4A-8F89-7952D64DF9BD

Q34041708-51C0F2BD-3983-4238-ADE7-BDBB1DB6243A

Q34041708-54E4BD1B-70CB-46F8-8097-552E99B52DE9

Q34041708-55AF18BE-7D76-460C-9400-CAFF9CFA1C7D

Q34041708-57F86326-69AA-477B-A9FD-B66F15F50310

Q34041708-608B6CAA-37FE-4832-A5A8-2FB28CE1441E

Q34041708-783B5682-D17E-4B29-83E5-FC28E7513BE6

P304

Q34041708-39F21B47-11C0-432E-9CF4-43D07A53DD06

P31

Q34041708-222ECF7F-8C27-4D9D-B1BB-7936A3EAC5C3

P356

Q34041708-BFB56A55-4D44-4DC5-9D43-3C3E37C647B2

P433

Q34041708-ACDE9127-C892-4647-B826-CCFC56072047

P478

Q34041708-3DBB1F05-1889-4CDF-90E1-D1EC14C0B89C

P50

Q34041708-04D64931-ADBE-4F41-8D63-6A942FC7107A

P577

Q34041708-B81E80E6-F62F-4A4D-BB4F-8988F10BDAF0

P698

Q34041708-07792C00-729D-4DDB-848B-66A2CEB347BE

P921

Q34041708-D0866F6F-525A-4E88-B8D3-94DEBB302FD3

P932

Q34041708-A7CD5BC0-8E7C-477E-A005-FC1F7B7DEE8A

P356

JTO.0000000000000076

P1433

Journal of Thoracic Oncology

P1476

PARAMOUNT: Descriptive subgrou ...... ous non-small-cell lung cancer

@en

P2093

Annamaria H Zimmermann

http://www.w3.org/2001/XMLSchema#string

Carla Visseren-Grul

http://www.w3.org/2001/XMLSchema#string

Eckart Laack

http://www.w3.org/2001/XMLSchema#string

Filippo de Marinis

http://www.w3.org/2001/XMLSchema#string

Luis G Paz-Ares

http://www.w3.org/2001/XMLSchema#string

Martin Reck

http://www.w3.org/2001/XMLSchema#string

Olivier Molinier

http://www.w3.org/2001/XMLSchema#string

Tarini Prasad Sahoo

http://www.w3.org/2001/XMLSchema#string

William John

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer

Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Chemotherapeutic management of stage IV non-small cell lung cancer.

Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN).

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.

Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy.

P304

205-213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/JTO.0000000000000076

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Cesare Gridelli

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24419418

http://www.w3.org/2001/XMLSchema#string

P921

P932

4132027

http://www.w3.org/2001/XMLSchema#string